- Home
- RPD vs VERA Comparison
RPD vs VERA Comparison
Compare RPD & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPD
- VERA
- Stock Information
- Founded
- RPD 2000
- VERA 2016
- Country
- RPD United States
- VERA United States
- Employees
- RPD N/A
- VERA N/A
- Industry
- RPD Computer Software: Prepackaged Software
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- RPD Technology
- VERA Health Care
- Exchange
- RPD Nasdaq
- VERA Nasdaq
- Market Cap
- RPD 1.3B
- VERA 1.4B
- IPO Year
- RPD 2015
- VERA 2021
- Fundamental
- Price
- RPD $20.32
- VERA $24.19
- Analyst Decision
- RPD Hold
- VERA Buy
- Analyst Count
- RPD 19
- VERA 8
- Target Price
- RPD $27.00
- VERA $64.29
- AVG Volume (30 Days)
- RPD 918.8K
- VERA 1.8M
- Earning Date
- RPD 08-07-2025
- VERA 08-05-2025
- Dividend Yield
- RPD N/A
- VERA N/A
- EPS Growth
- RPD N/A
- VERA N/A
- EPS
- RPD 0.43
- VERA N/A
- Revenue
- RPD $855,361,000.00
- VERA N/A
- Revenue This Year
- RPD $2.75
- VERA N/A
- Revenue Next Year
- RPD $3.32
- VERA N/A
- P/E Ratio
- RPD $45.98
- VERA N/A
- Revenue Growth
- RPD 4.67
- VERA N/A
- 52 Week Low
- RPD $17.83
- VERA $18.53
- 52 Week High
- RPD $44.48
- VERA $51.61
- Technical
- Relative Strength Index (RSI)
- RPD 46.26
- VERA 61.33
- Support Level
- RPD $19.57
- VERA $21.71
- Resistance Level
- RPD $21.26
- VERA $23.07
- Average True Range (ATR)
- RPD 0.68
- VERA 1.25
- MACD
- RPD 0.05
- VERA 0.21
- Stochastic Oscillator
- RPD 34.24
- VERA 88.89
About RPD Rapid7 Inc.
Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.